Mar 04 2010

Astrazeneca Invests $2.1 million in support of Cancer Resarch in BC

Investment recognizes world class oncology research and development expertise at BC Cancer Agency and Vancouver Prostate Centre.MISSISSAUGA, ONTARIO – AstraZeneca Canada is pleased to announce a $500,000 investment to support oncology research and development at the BC Cancer Agency (BCCA).

Read more
Jan 25 2010

Vancouver Prostate Centre and Astrazeneca Extend Collaborative Research Agreement

VANCOUVER, BRITISH COLUMBIA – The Vancouver Prostate Centre announced today an extended collaboration with AstraZeneca that sees the Vancouver Prostate Centre receive $700,000 over two years towards research that targets treatment-resistant prostate cancer.The research, which is being coordinated through the Vancouver Prostate Centre ― a Centre of Excellence for Commercialization and Research ― evaluates AstraZeneca's androgen receptor-targeting small molecules, as well as, molecules that target cell cycle growth to slow, or stop, tumour proliferation in prostate cancer.Specifically this re

Read more
Dec 03 2009

Pfizer and B.C. Launch $9m Collaboration to Tackle Cancer

VANCOUVER – Pfizer is entering into a three-year, $9-million research collaboration with the BC Cancer Agency and the Vancouver Prostate Centre, a University of British Columbia (UBC) and Vancouver General Hospital (VGH) Centre of Excellence, to tackle new treatment avenues for breast, ovarian and prostate cancer.

Read more
Nov 24 2009

MDRNA Expands RNAi Bladder Cancer Program

Decision to Expand Based Upon Promising Pre-Clinical ResultsBOTHELL, WA – (MARKETWIRE via COMTEX) – MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced the extension and expansion of its collaboration with the Vancouver Prostate Centre (VPC), covering the discovery and development of RNAi-based therapeutics for the treatment of bladder cancer.

Read more
Nov 04 2009

OGX-427 in Clinical Trial for Bladder Cancer

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the first patient has been dosed in an open label, dose-escalation, Phase 1 clinical trial evaluating OGX-427 when administered directly into the bladder in patients with bladder cancer.In preclinical studies conducted by the Vancouver Prostate Centre, OGX-427 had single-agent activity in multiple cancers. In preclinical models of bladder cancer, the investigators observed that bladder cancer tumors were significantly smaller six weeks after OGX-427 administration compared to the control group.View full Press Release

Read more
Nov 02 2009

Prostate Centre-Discovered Cancer Drugs Show Promise

Two cancer drugs discovered at Vancouver Prostate Centre show promise in treating prostate and other cancersDuring the recent American Society of Clinical Oncology (ASCO) annual meeting in Orlando, Florida, promising results from two drugs (OGX-011 and OGX-427) discovered at the Vancouver Prostate Centre were presented in two separate oral presentations, an unprecedented milestone for the Centre.The Vancouver Prostate Centre is a UBC and CECR National Centre of Excellence whose integrated team-science approach and state of the art infrastructure facilitate rapid bench-to-bedside translation

Read more
Sep 24 2009

Construction Starts on New Research Centre

VANCOUVER – Premier Gordon Campbell helped launch the official groundbreaking of the new seven-storey, Robert H.N. Ho Research Centre at Vancouver General Hospital, built in part thanks to the generous donation of $15 million from Mr. Robert Ho."Patients with cancer, people with bone health issues, and those with mobility challenges will all benefit from the research that will take place in this facility," said Premier Campbell. "Hundreds of scientists and clinicians will work in this building, researching and developing new treatments and cures for disease."The 69,350 sq. ft.

Read more



Dec 07 2017

Dr. Wyatt receives a CIHR Early Career Investigator Award

Dr. Alex Wyatt has been awarded a CIHR Early Career Investigator Award for $345,000 over 3 years.  His project aims to develop a procedure that will enable the identification of metastatic bladder cancer patients most likely to respond to specific therapies.

Read more